Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1316Neoplasms 1104Carcinoma, Non-Small-Cell Lung 916Prostatic Neoplasms 747Colorectal Neoplasms 645Lung Neoplasms 621Neoplasm Metastasis 470Multiple Myeloma 444Leukemia, Myeloid, Acute 440Pancreatic Neoplasms 392Ovarian Neoplasms 388Melanoma 346Carcinoma, Hepatocellular 308Brain Neoplasms 290Squamous Cell Carcinoma of Head and Neck 285Recurrence 285Glioblastoma 260Stomach Neoplasms 252Head and Neck Neoplasms 250Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Carcinoma, Renal Cell 237Lymphoma 235Triple Negative Breast Neoplasms 233Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Hematologic Neoplasms 216Urinary Bladder Neoplasms 212Lymphoma, Non-Hodgkin 203Glioma 202Sarcoma 200

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × 90 days × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡